Patent settlements fostered by the makers of branded drugs are the source of needless government spending, according to The Washington Times' weekly Golden Hammer. Representing PhRMA, Diane Bieri says that intellectual property protections allow companies to spend time and money developing new treatments that improve public health.

Related Summaries